Roche's $25M Astex deal is small money upfront, but a big signal for breast cancer goals

Roche's Genentech deepens its oncology pipeline bets by paying Astex $25M upfront (up to $490M+ milestones) for early breast cancer compounds.

Raccontata daendpoints.news